Oncology/Hematology
News, opinions and meeting coverage in oncology/hematology.
— All-cause mortality reductions approached 50%, including advanced cancers
Latest in Oncology/Hematology
More than 60% of brain metastases had a clinically actionable alteration
Drug is approved in combination with fludarabine
A 67-year-old man visited the doctor for a cyst-like lesion that developed on his face 3 months prior.
Early-stage study showed improved response rates and survival when added to standard of care
A 67-year-old man visited the doctor for a cyst-like lesion that developed on his face 3 months prior.
Early-stage study showed improved response rates and survival when added to standard of care
Oncology/Hematology Case Studies
Rare condition can be deadly without early diagnosis and treatment
Nonspecific presentation impedes early diagnosis of rare indolent tumor in older man
Be aware of the potential for secondary malignancy in relation to LCH diagnosis, researchers urge
More in Oncology/Hematology
Health news and commentary gathered by 鶹ý staff
Median PFS in GEP-NETs increased from 11.5 to 29.7 with addition of lanreotide to everolimus
Tests do not appear to consistently influence risk classification or treatment decisions
Sometimes doctors communicate in 'medicalease' and help less than we think we do
Also in TTHealthWatch: improving outcomes in large strokes
Analyses of current or former use, duration of use, social factors fail to show an association
Only 44% of HPV-positive patients with negative cytologic findings were retested within 16 months
In trial, datopotamab deruxtecan increased progression-free survival by 2 months
News, features, and commentary about cancer-related issues
25 drugs chosen so far comprise about a third of Medicare Part D spending on prescription drugs
Health news and commentary gathered by 鶹ý staff
Mortality hazard reduced by one third at 7 years versus trastuzumab
While well tolerated, there was also no significant reduction in risk of recurrence over placebo
Biden touts Medicare drug price negotiation and gun safety law, but also warns about AI's dangers
